Nuclea Biotherapies LLC, an oncology diagnostics company with offices in Pittsfield and Worcheser, Mass., wrapped up a $3.4 million funding round, according to regulatory documents filed Thursday with the U.S. Securities and Exchange Commission.
In July the company said it had closed on $1 million in new financing through the sale of preferred stock units. Since that time, three additional investor groups came aboard, including New York’s Private Equity Investors Fund.
Richard Vietor, a venture partner at PEI, was tapped for a new seat on Nuclea’s board of directors. Specific investor amounts and terms of the deal were not disclosed.
Nuclea’s three subsidiaries make biomarker chips used by pharmaceutical companies for cancer research. Company founder and CEO Patrick Muraca earlier this year also received a patent for a new catheter-based surgical probe.
